The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

NCT05741359 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-hodgkin Lymphoma,B Cell

Interventions

DRUG: CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection

Sponsor

Bioray Laboratories

Collaborators

[object Object]
[object Object]
[object Object]